- PHIO Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
10-Q/A Filing
Phio Pharmaceuticals (PHIO) 10-Q/A2017 Q3 Quarterly report (amended)
Filed: 26 Mar 18, 12:00am
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of RXi Pharmaceuticals Corporation (the “Company”) on Form10-Q/A for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and result of operations.
/s/ Geert Cauwenbergh |
Geert Cauwenbergh, Dr. Med. Sc. |
President, Chief Executive Officer and acting Chief Financial Officer |
(as Principal Executive and Financial Officer) |
March 26, 2018